FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia Clinical Trial
AVM Biotechnology, a clinical-stage company, announced FDA permission to modify its ongoing non-Hodgkin's lymphoma/leukemia clinical study.
July 14, 2021
by americanpharmaceuticalreview
Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
May 11, 2021
by worldpharmanews
PRA Health Sciences, LLS Collaborate on Global Trial for Children with Acute Leukemia
The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences has announced a partnership to launch a global master clinical trial to develop new treatments for children with relapsed acute leukemia.
September 7, 2020
by americanpharmaceuticalreview
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study
Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib (ABL001) vs. bosutinib.
September 1, 2020
by pharmaceutical-business-review
Pharmaceutical News of the Week (July. 20th-July. 24th) | PharmaSources.com - Updates on R&D
The hottest event of the week was the official kick-off of the centralized procurement of the third batch of pharmaceutical products organized in China, with 86 specifications started to be acquired the basic information.
July 29, 2020
by PharmaSources/Caicai
Vitamin B6, leukemia's deadly addiction
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and ...
January 14, 2020
by worldpharmanews
Rafael Expands CPI-613 Trial
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia.
December 27, 2019
by americanpharmaceuticalreview
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017
For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia & Lymphoma.
December 27, 2019
by drugs
Risk Score Developed to Help ID Heart Failure Risk in Leukemia
In a study published in the December issue of JACC: CardioOncology, authors investigated the occurrence and developed a risk score to determine the risk for heart failure in patients with ...
December 20, 2019
by drugs
Leukemia, lymphoma squarely in sights of new class of drugs
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of ...
December 9, 2019
by worldpharmanews
Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.
September 26, 2019
by worldpharmanews
Leukemia drug shows promise for treating a childhood brain cancer
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor ...
September 25, 2019
by worldpharmanews